Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
Skin Cancer Risk Reduced for Patients Treated With Nicotinamide
THURSDAY, Sept. 18, 2025 -- For patients treated with nicotinamide, the risk for skin cancer is reduced, especially when initiated after a first skin cancer...
Once-Weekly Semaglutide 7.2 mg Beats Placebo for Obesity
THURSDAY, Sept. 18, 2025 -- In adults with obesity and those with type 2 diabetes and obesity, once-weekly semaglutide 7.2 mg is superior to placebo for body...
Evidence Insufficient to Determine Benefits of Multicancer Screening Tests
THURSDAY, Sept. 18, 2025 -- No controlled studies report benefits of screening with multicancer detection (MCD) tests, according to a study published online...
Acupuncture Beneficial for Chronic Low Back Pain in Older Adults
THURSDAY, Sept. 18, 2025 -- For older adults with chronic low back pain (CLBP), acupuncture is associated with improved CLBP-related disability and benefits...
Guidance Issued for Creation of pAVFs for Hemodialysis Access
THURSDAY, Sept. 18, 2025 -- In a guidance document issued by the Society of Interventional Radiology Practice and published online Sept. 9 in the Journal of...
Orange B Food Dye May Soon Be Removed From U.S. Market, FDA Says
THURSDAY, Sept. 18, 2025 — Federal health officials want to take Orange B — an artificial food dye that hasn’t been used in more than four decades — off the bo...
Hall-of-Famer Dan Marino Shares 20-Year Struggle With Liver Disease
THURSDAY, Sept. 18, 2025 — Football legend Dan Marino has disclosed that he has been living with a serious liver condition for nearly 20 years. The former M...
OpenAI Launches Teen-Safe ChatGPT With Parental Controls
THURSDAY, Sept. 18, 2025 — Teenagers chatting with ChatGPT will soon see a very different version of the tool — one built with stricter ways to keep them safe...
Boar’s Head Faces Pressure From Congress Over Plans to Reopen After Listeria Deaths
THURSDAY, Sept. 18, 2025 — Federal officials are raising concerns about whether a Virginia Boar’s Head deli meat plant, linked to last year’s deadly listeria o...
Experimental Patch Provides Real-Time Feedback On Muscle Performance
THURSDAY, Sept. 18, 2025 — An experimental wireless patch might help injured athletes better recover from muscle tears, sprains and strains, according to a n...
FDA Approves Enbumyst (bumetanide) Nasal Spray for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease
HENDERSON, Nev.--(BUSINESS WIRE) September 15, 2025 --Corstasis Therapeutics Inc., an innovative biopharmaceutical company providing enhanced outpatient...
Intercept Announces Voluntary Withdrawal of Ocaliva for Primary Biliary Cholangitis (PBC) from the US Market; FDA Places US Clinical Trials on Hold
September 12, 2025. MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of...
FDA Approves Selumetinib for Pediatric Patients 1 year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas
On September 10, 2025, the Food and Drug Administration approved selumetinib (Koselugo, AstraZeneca Pharmaceuticals LP) granules and capsules for pediatric...
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Sep. 10, 2025-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery...
FDA Approves Inlexzo (gemcitabine intravesical system) for the Treatment of Non-Muscle Invasive Bladder Cancer
September 9, 2025. RARITAN, N.J., September 9, 2025 /PRNewswire/ – Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration...
U.S. FDA Approves Expanded Indication for Vonvendi [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
OSAKA, Japan and CAMBRIDGE, Massachusetts, September 5, 2025 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration...
Stealth Biotherapeutics Announces FDA Acceptance of Elamipretide NDA Resubmission
NEEDHAM, Mass., Aug. 21, 2025 /PRNewswire/ — Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and...
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
WARREN, N.J., Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a...
Stealth Biotherapeutics Resubmits New Drug Application for Elamipretide for the Treatment of Barth Syndrome
NEEDHAM, Mass., Aug. 18, 2025 /PRNewswire/ — Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development...
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
NEW HAVEN, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today with its partner Pfizer Inc. (NYSE: PFE), announced that the U.S. Food...
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company...
Baxdrostat Demonstrated Statistically Significant and Clinically Meaningful Reduction in Systolic Blood Pressure in Patients with Hard-to-Control Hypertension in the BaxHTN Phase III Trial
30 August 2025 -- Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated a statistically significant and clinically meaningful r...
Regeneron Announces Positive Results from Phase 3 Trial of Cemdisiran in Generalized Myasthenia Gravis
TARRYTOWN, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the primary and key secondary endpoints...
Lilly's Oral GLP-1, Orforglipron, is Successful in Third Phase 3 Trial, Triggering Global Regulatory Submissions This Year for the Treatment of Obesity
INDIANAPOLIS, Aug. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-2 trial...
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
NEWARK, CA / ACCESS Newswire / August 25, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or "the Company") announced today that rusfertide, a potential...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.